Format

Send to

Choose Destination
Radiat Oncol J. 2017 Sep;35(3):268-273. doi: 10.3857/roj.2017.00199. Epub 2017 Sep 29.

Role of fractionated radiotherapy in patients with hemangioma of the cavernous sinus.

Author information

1
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Abstract

PURPOSE:

We performed this retrospective study to investigate the outcomes of patients with hemangioma of the cavernous sinus after fractionated radiotherapy.

MATERIALS AND METHODS:

We analyzed 10 patients with hemangioma of the cavernous sinus who were treated with conventional radiotherapy between January 2000 and December 2016. The median patient age was 54 years (range, 31-65 years), and 8 patients (80.0%) were female. The mean hemangioma volume was 34.1 cm3 (range, 6.8-83.2 cm3), and fractionated radiation was administered to a total dose of 50-54 Gy with a daily dose of 2 Gy.

RESULTS:

The median follow-up period was 6.8 years (range, 2.2-8.8 years). At last follow-up, the volume of the tumor had decreased in all patients. The average tumor volume reduction rate from the initial volume was 72.9% (range, 18.9-95.3%). All 10 of the cranial neuropathies observed before radiation therapy had improved, with complete symptomatic remission in 9 cases (90%) and partial remission in 1 case (10%). No new acute neurologic impairments were reported after radiotherapy. One probable compressive optic neuropathy was observed at 1 year after radiotherapy.

CONCLUSION:

Fractionated radiotherapy achieves both symptomatic and radiologic improvements. It is a well-tolerated treatment modality for hemangiomas of the cavernous sinus.

KEYWORDS:

Cavernous sinus; Hemangioma; Radiotherapy

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center